Tissue Regenix Group (TRX)

 

TRX Share PerformanceMore

52 week high21.000 03/01/17
52 week low5.500 08/12/17
52 week change -12.625 (-64.74%)
4 week volume45,991,901 18/11/17

Technical Insight

Login or Register to access technical insights.

Latest NewsMore

Tissue Regenix CFO resigns

Tissue Regenix Group said chief financial officer Paul Devlin has resigned. The company said it would commence a search...

Directorate Change

RNS Number: 0705Y Tissue Regenix Group PLC 01 December 2017 Tissue Regenix Group plc Directorate Change Leeds, 01 December 2017 - Tissue Regenix Group (AIM:TRX) ("Tissue Regenix" or "The Group") the regenerative medical devices company, announces that the Board has accepted the resignation of Paul Devlin, CFO. The Board will commence a process to...

Issue of Equity

RNS Number: 0678Y Tissue Regenix Group PLC 01 December 2017 Tissue Regenix Group Plc Issue of equity and total voting rights Leeds, 01 December 2017 - Tissue Regenix Group plc (AIM:TRX) ("Tissue Regenix" or "the Company"), the regenerative medical devices company,announces that it has today issued and allotted 552,337 ordinary shares of 0.5p each in the C...

Tissue Regenix appoints CEO

Tissue Regenix, a regenerative medical devices company, has appointed Steve Couldwell as chief executive officer of the gr...

Appointment of CEO

RNS Number: 3338V Tissue Regenix Group PLC 02 November 2017 Tissue Regenix Group plc Appointment of CEO Steve Couldwell appointed Group CEO Leeds, 02 November 2017 - Tissue Regenix Group (AIM:TRX) ("Tissue Regenix" or "The Group") the regenerative medical devices company announces the appointment of Steve Couldwell, as Chief Executive Off...

Directorate Change

RNS Number: 8786T Tissue Regenix Group PLC 18 October 2017 [This announcement contains inside information.] Tissue Regenix Group plc Directorate Change Leeds, 18 October 2017 - The Board of Tissue Regenix Group plc (AIM:TRX) ("Tissue Regenix" or "The Group") today announces that Antony Odell, Chief Executive Officer (CEO), will be stepping down fro...

Hardman Research: Dual revenue stream growth

RNS Number: 2491T Tissue Regenix Group PLC 11 October 2017 Hardman Research: Dual revenue stream growth Dual revenue stream growth - TRX has a broad portfolio of regenerative medicine products developed from decellularised human and porcine soft tissues for the wound care, orthopaedics, and cardiac markets. Since the launch of DermaPure, focus has...

Unaudited Interim Results

RNS Number: 1381S Tissue Regenix Group PLC 28 September 2017 Tissue Regenix Group plc Unaudited Interim Results for the six months ended 30 June 2017 Leeds, 28 th September 2017 - Tissue Regenix Group (AIM:TRX) "Tissue Regenix" or "The Group", the regenerative medical devices company, today announces its unaudited interim results for the six months en...

Fundamental DataMore

EPS-1.27
Dividend yield0 %

Latest discussion posts More

  • I used to have....

    ....great hope for this company. Problem is, there's been so much delay in improving the financials and now losing the CEO and CFO without ANY explanation. Frankly, it takes ...
    8-Dec-2017
    waytogo333
  • buy / sell price

    offered 5.66 to sell and 5.65 to buy... abit odd ?
    7-Dec-2017
    spit49oon
  • Looks like ...

    ....It?s not just the BOD that are heading for the door ! TP
    7-Dec-2017
    theprior

Users' HoldingsMore

Users who hold Tissue Regenix Group also hold..

Codes & Symbols

ISINGB00B5SGVL29
SymbolsTRX, LSE:TRX, TRX.L, TRX:LN, LON:TRX, XLON:TRX

Join interactive investor

  • £22.50 fixed quarterly charge includes £22.50 in trading credits
  • £10 per trade or £6 for frequent traders
  • No % platform fees
  • £1 per trade for regular investment or dividend reinvestment

Open an account